Provided by Tiger Fintech (Singapore) Pte. Ltd.

BriaCell Therapeutics Corp.

3.84
+0.390011.30%
Post-market: 3.840.00000.00%19:26 EDT
Volume:62.14K
Turnover:230.54K
Market Cap:14.24M
PE:-0.29
High:3.89
Open:3.73
Low:3.45
Close:3.45
Loading ...

BriaCell Highlights Promising Breast Cancer Trial Results

TIPRANKS
·
26 Nov 2024

BriaCell to highlight OS, clinical benefit data of Bria-IMT in MBC patients

TIPRANKS
·
26 Nov 2024

BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer

GlobeNewswire
·
26 Nov 2024

BriaCell director Marc Lustig resigns

TIPRANKS
·
25 Nov 2024

BriaCell Provides Update to its Board of Directors

GlobeNewswire
·
25 Nov 2024

BriaCell Advances Cancer Treatment with New Trial

TIPRANKS
·
21 Nov 2024

BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study

GlobeNewswire
·
21 Nov 2024

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

GlobeNewswire
·
08 Nov 2024

BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13

GlobeNewswire
·
04 Nov 2024

BriaCell Therapeutics Faces Uncertain Financial Future

TIPRANKS
·
02 Nov 2024

Briacell Therapeutics Corp reports results for the quarter ended in July 31 - Earnings Summary

Reuters
·
29 Oct 2024

BriaCell Higher as it Reports "Standard-Beating" Survival Data From Phase 2 Study

MT Newswires
·
22 Oct 2024

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

GlobeNewswire
·
22 Oct 2024

BriaCell to Complete Patient Enrollment for Phase 3 Breast Cancer Study by Mid-2025; Shares Rise

MT Newswires Live
·
15 Oct 2024

BriaCell gains after update on late-stage trial for lead asset

seekingalpha
·
15 Oct 2024

BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study

GlobeNewswire
·
15 Oct 2024